2026 Q1 -tulosraportti
14 päivää sitten
‧28 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 116 | - | - | ||
| 384 | - | - | ||
| 8 230 | - | - | ||
| 6 638 | - | - | ||
| 399 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 592 882 | 1 592 882 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 592 882 | 1 592 882 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 19.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 19.5. | ||
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 13.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 t sitten · MuokattuI read it to mean that the rights issue is due to a decision to finance a new study, which was not foreseen in the previous announcement about the company's financing until 2028: "Företrädesemissionen och låneavtalet genomförs främst för att säkra finansiering för inledande av en fas Ib-studie där nadunolimab kombineras med en RAS-hämmare" And that by doing so, one will naturally also lack funds for what was originally budgeted: "samt fortsatt utveckling och positionering avseende bukspottkörtelcancer, utvidgande av den pågående kliniska fas Ib/IIa-studien och förberedelser av en fas IIb-studie avseende myelodysplastiskt syndrom/akut myeloisk leukemi." It's probably the same as what Redeye wrote on May 22: "Redeye comments on Cantargia's first quarter report 2026. We have revised our valuation and timeline assumptions following Cantargia’s decision to pursue a combination study of nadunolimab with a RAS inhibitor rather than a pivotal programme in combination with gemcitabine/nab-paclitaxel. We believe this will be fertile ground for future licensing deals. This results in a slightly lower new base case." One can disagree with initiating "inledande av en fas Ib-studie där nadunolimab kombineras med en RAS-hämmare" now instead of waiting until there were funds for it. And I do. But now that it has been initiated, the chosen financing model and the limited förträdesemission are significantly better and more cleverly executed and announced than what we are used to seeing in biotech - and the share price reaction is a violent overreaction. Isn't the share price reaction also due to the fact that we are used to common shares plummeting completely in the many other amateurish biotech emissions we are used to experiencing. All else being equal, the share price today should be 2,8: 9 shares at 2,92 plus 2 new shares at 2,25 = a total of 11 shares for 30,78 corresponding to 2,80 per share,
·29.5.This shows how dissatisfied we shareholders are with that emission, otherwise it would not fall 10 % below the emission price
·19 t sitten · MuokattuThe shareholders are dissatisfied with the lie that they had enough money until 2028 and the uncertainty about an emission was gone until 2028. Then it came already in 2026. Get Hilde removed. Since she arrived, confidence in Cantargia has fallen to rock bottom and Hilde has only caused share price drops. Get her away! She adds NOTHING of value to Cantargia. The board will soon feel the shareholders and be forced to remove her. Incompetent hag.- ·29.5. · MuokattuInsane share price drop. Finally a rights issue, which is carried out sensibly and transparently from the start - and the share price plummets below the issue price and falls approx. 80 øre, where according to my quick mental estimate it should only have fallen 12 øre. 9 shares at 2.92 plus 2 new shares at 2.25 = total 11 shares for 30.78 corresponding to 2.80 per share, which all else being equal should be today's price.
- ·29.5.Agrees with dengamlefisker that the board/management enriches themselves compared to how far the company is with their products; they could have waited until there was approval/partner/ and sales and the share price was at a completely different level, then they could award themselves bonuses and not now where they ask us to pay their high salaries/bonuses, which should not have been approved; the only positive thing one can say about this is that they come out with the issue price from the start and not like others who wait for months to come out with it, and all that time the share price trickles down; here we know where the price level lies.
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
14 päivää sitten
‧28 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sitten · MuokattuI read it to mean that the rights issue is due to a decision to finance a new study, which was not foreseen in the previous announcement about the company's financing until 2028: "Företrädesemissionen och låneavtalet genomförs främst för att säkra finansiering för inledande av en fas Ib-studie där nadunolimab kombineras med en RAS-hämmare" And that by doing so, one will naturally also lack funds for what was originally budgeted: "samt fortsatt utveckling och positionering avseende bukspottkörtelcancer, utvidgande av den pågående kliniska fas Ib/IIa-studien och förberedelser av en fas IIb-studie avseende myelodysplastiskt syndrom/akut myeloisk leukemi." It's probably the same as what Redeye wrote on May 22: "Redeye comments on Cantargia's first quarter report 2026. We have revised our valuation and timeline assumptions following Cantargia’s decision to pursue a combination study of nadunolimab with a RAS inhibitor rather than a pivotal programme in combination with gemcitabine/nab-paclitaxel. We believe this will be fertile ground for future licensing deals. This results in a slightly lower new base case." One can disagree with initiating "inledande av en fas Ib-studie där nadunolimab kombineras med en RAS-hämmare" now instead of waiting until there were funds for it. And I do. But now that it has been initiated, the chosen financing model and the limited förträdesemission are significantly better and more cleverly executed and announced than what we are used to seeing in biotech - and the share price reaction is a violent overreaction. Isn't the share price reaction also due to the fact that we are used to common shares plummeting completely in the many other amateurish biotech emissions we are used to experiencing. All else being equal, the share price today should be 2,8: 9 shares at 2,92 plus 2 new shares at 2,25 = a total of 11 shares for 30,78 corresponding to 2,80 per share,
- ·29.5.This shows how dissatisfied we shareholders are with that emission, otherwise it would not fall 10 % below the emission price·19 t sitten · MuokattuThe shareholders are dissatisfied with the lie that they had enough money until 2028 and the uncertainty about an emission was gone until 2028. Then it came already in 2026. Get Hilde removed. Since she arrived, confidence in Cantargia has fallen to rock bottom and Hilde has only caused share price drops. Get her away! She adds NOTHING of value to Cantargia. The board will soon feel the shareholders and be forced to remove her. Incompetent hag.
- ·29.5. · MuokattuInsane share price drop. Finally a rights issue, which is carried out sensibly and transparently from the start - and the share price plummets below the issue price and falls approx. 80 øre, where according to my quick mental estimate it should only have fallen 12 øre. 9 shares at 2.92 plus 2 new shares at 2.25 = total 11 shares for 30.78 corresponding to 2.80 per share, which all else being equal should be today's price.
- ·29.5.Agrees with dengamlefisker that the board/management enriches themselves compared to how far the company is with their products; they could have waited until there was approval/partner/ and sales and the share price was at a completely different level, then they could award themselves bonuses and not now where they ask us to pay their high salaries/bonuses, which should not have been approved; the only positive thing one can say about this is that they come out with the issue price from the start and not like others who wait for months to come out with it, and all that time the share price trickles down; here we know where the price level lies.
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 116 | - | - | ||
| 384 | - | - | ||
| 8 230 | - | - | ||
| 6 638 | - | - | ||
| 399 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 592 882 | 1 592 882 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 592 882 | 1 592 882 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 19.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 19.5. | ||
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 13.5.2025 |
2026 Q1 -tulosraportti
14 päivää sitten
‧28 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 19.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 19.5. | ||
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 13.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sitten · MuokattuI read it to mean that the rights issue is due to a decision to finance a new study, which was not foreseen in the previous announcement about the company's financing until 2028: "Företrädesemissionen och låneavtalet genomförs främst för att säkra finansiering för inledande av en fas Ib-studie där nadunolimab kombineras med en RAS-hämmare" And that by doing so, one will naturally also lack funds for what was originally budgeted: "samt fortsatt utveckling och positionering avseende bukspottkörtelcancer, utvidgande av den pågående kliniska fas Ib/IIa-studien och förberedelser av en fas IIb-studie avseende myelodysplastiskt syndrom/akut myeloisk leukemi." It's probably the same as what Redeye wrote on May 22: "Redeye comments on Cantargia's first quarter report 2026. We have revised our valuation and timeline assumptions following Cantargia’s decision to pursue a combination study of nadunolimab with a RAS inhibitor rather than a pivotal programme in combination with gemcitabine/nab-paclitaxel. We believe this will be fertile ground for future licensing deals. This results in a slightly lower new base case." One can disagree with initiating "inledande av en fas Ib-studie där nadunolimab kombineras med en RAS-hämmare" now instead of waiting until there were funds for it. And I do. But now that it has been initiated, the chosen financing model and the limited förträdesemission are significantly better and more cleverly executed and announced than what we are used to seeing in biotech - and the share price reaction is a violent overreaction. Isn't the share price reaction also due to the fact that we are used to common shares plummeting completely in the many other amateurish biotech emissions we are used to experiencing. All else being equal, the share price today should be 2,8: 9 shares at 2,92 plus 2 new shares at 2,25 = a total of 11 shares for 30,78 corresponding to 2,80 per share,
- ·29.5.This shows how dissatisfied we shareholders are with that emission, otherwise it would not fall 10 % below the emission price·19 t sitten · MuokattuThe shareholders are dissatisfied with the lie that they had enough money until 2028 and the uncertainty about an emission was gone until 2028. Then it came already in 2026. Get Hilde removed. Since she arrived, confidence in Cantargia has fallen to rock bottom and Hilde has only caused share price drops. Get her away! She adds NOTHING of value to Cantargia. The board will soon feel the shareholders and be forced to remove her. Incompetent hag.
- ·29.5. · MuokattuInsane share price drop. Finally a rights issue, which is carried out sensibly and transparently from the start - and the share price plummets below the issue price and falls approx. 80 øre, where according to my quick mental estimate it should only have fallen 12 øre. 9 shares at 2.92 plus 2 new shares at 2.25 = total 11 shares for 30.78 corresponding to 2.80 per share, which all else being equal should be today's price.
- ·29.5.Agrees with dengamlefisker that the board/management enriches themselves compared to how far the company is with their products; they could have waited until there was approval/partner/ and sales and the share price was at a completely different level, then they could award themselves bonuses and not now where they ask us to pay their high salaries/bonuses, which should not have been approved; the only positive thing one can say about this is that they come out with the issue price from the start and not like others who wait for months to come out with it, and all that time the share price trickles down; here we know where the price level lies.
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 116 | - | - | ||
| 384 | - | - | ||
| 8 230 | - | - | ||
| 6 638 | - | - | ||
| 399 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 592 882 | 1 592 882 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 592 882 | 1 592 882 | 0 | 0 |